BRIACELL THERAP BCTX
4.32
0.04
0.93%
as of 25 Sep
- Market cap
- $37.2M
- P/E
- 1.9×
Follow BCTX
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Older periods | |
|---|---|---|---|---|---|
| (173.55%) | (177.26%) | (439.51%) | (359.23%) |
+8 more TTM periods Free account |
|
| (139.20%) | (137.98%) | (244.43%) | (191.21%) | ||
ROIC |
(3,311.00%) | (6,192.94%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(138.48%) | (101.34%) | (345.68%) | (161.97%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.33) | (11.05) | (15.35) | (66.58) | |
Free Cash Flow |
(31.41) | (30.97) | (28.92) | (28.17) | |
Capital Expenditures |
(0.58) | — | — | — | |
| Other line items | |||||
Cash ROIC |
(66.70%) | (51.51%) | (148.11%) | (80.03%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.00 | 1.04 | 1.01 | 1.07 | |
Depreciation/Fixed assets |
0.32 | 0.42 | 0.39 | 0.36 | |
Capex/Depreciation |
(5.17) | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.25) | (11.05) | (15.35) | (66.58) | |
Capex per Share |
(0.08) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | — | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates